Member Info for HereforHemo

cs It’s difficult to predict where the SP’s going on this one, as nobody is quite sure where they are up to with their pre clinical studies for CAR-T, CDX and CBR and as such when they are likely to submit IND applications and how long the process will take from IND to clinical trials. Vlad had stated that CAR-T IND application would be this summer although not sure whether they are looking to do this sooner now. Depends on FDA feedback I suppose and whether (if the pre-clinical work is complete) it is granted fast track status. HEMO was around 8p before the funding debacle and even after dilution should still have been around 4p imo, bearing in mind they are so much further forward in their developments. I’m hoping for an SP around 7p by the end of Q2 as I expect a positive CBR update to be released by then as well. But as I say, everything is total guesswork until HEMO actually tell us where they’re up to with the science on all of their candidates.

I would find an RNS stating their are no FDA objections for HEMO to move forward with an IND application for HEMO CAR-T far from low key, it would be a key milestone towards an inflection point. And for information, the human trials will consistent of 20 patients, assuming it gets that far.

Hemos down more than oil or Cyrpto? Just be thankful Vlad said there’d be news soon..no really soon..okay one day.

Everyone is here to turn a profit. Those who participate in placings are just handed a 25% discount that enables them to flip their shares earlier. The problem with Hemo’s placement was that firstly it should have been at 7p and not 1.5p and secondly it wasn’t offered as an open offer to existing shareholders (with the exception of one or two), it was offered to select wealthy individuals who had already sold out of HEMO on the spike with a healthy profit and who immediately sold again, taking their 25% profit and crashing the SP. So if you think Vlad and the BOD have done a good job with financing the company through the above and the disastrous CLN agreement I think you’ll find you’re in the minority.

JHFH I agree with you, HEMO have probably made significant progress on the science but the problem is they still haven’t told us. Vlad said in an interview, I think last April, shareholders will be happy when they see where we’ve spent the money.. I look forward to hearing. To clarify, I’m confident they will become a clinical company, I just have absolutely no idea when.

Mr India Unfortunately to date Vlad has not delivered on anything promised to shareholders leading to a horrendous 2021 for most investors. Although there have been some promising RNS’s on partnerships for both CAR-T and CDX they are both, in my opinion, running at least a year late in their development. That being said, there has been a request to the FDA for a pre IND meeting and that does have to occur by the middle of February at the latest. I understand that following the meeting Hemogenyx will be releasing information on what the FDA think about the forthcoming CAR-T IND application and as others have said, if the feedback is positive then we should see a bounce in the SP as it would basically be a green light that they will go into clinical trials. If you’re an investor you have to think with the expertise HEMO have assembled around them it will indeed be positive, else why ask for the meeting in the first place? If indeed it is positive feedback we may also find out whether it can be assigned as a breakthrough therapy or as a fast track application. Either would allow clinical trials to commence in the very near future. However, until the meeting is held (and there’s been no official confirmation from HEMO that is was actually granted) and until we know the outcome, people are going to sit on the fence and wait. Vlad is STILL running Hemogenyx in stealth mode as if it’s a private company so until we get something TANGIBLE to match his bullish statements personally I don’t see anything changing with the SP. We’ve still no idea whether pre clinical work has completed with CDX or CBR and have no real idea where they’re at on their development cycle, although the vibes sound positive. So my take, you either believe their product candidates will get into the clinic in which case you hold and wait for the substantial rerate, or you don’t, in which case it’s better to sell up, take your loss and move on.

I wouldn’t worry about it. The SP has been around the 1.65 to 2p range for around a year. No reason to expect it to change until the FDA feedback in around a months time, in my opinion anyway. Unless of course we get a CBR update, which should be soon. Unfortunately it might be Vlads soon as stated in June so who knows. Just a waiting game now, could be weeks or could be months, only time will tell.

I agree JHFh, CAR-T will be licensed upon clinical proof of concept, with a substantial upfront payment with milestone payments taking it through phase 2/3 trials and hopefully into manufacturing. Should the pre IND meeting go well my hope is that it will designated as a breakthrough therapy which ensures a fast track into clinical trials. Phase 1 will only be 20 patients so we should know the results pretty quickly after they commence. Vlad has stated their product candidates will be worth 20 to 30 times the value of a pre clinical drug so a lot to look forward to this year. With CDX and CBR we have three throws of the dice. Anyone of these would be transformational for the company. Personally I think we’ll hear the FDA feedback from CAR-T within a month. Hopefully it’s then game on for Hemogenyx. Can’t think of any other small cap that has the potential to rerate as much as HEMO. 5 to 7 fold increase on the cards within 6 months with a little luck. I remain confident of the science, of Vlad and his team. Not long now guys. GLA!

Certainly wish I’d waited for my top up but nothing you can do after you’ve pressed the buy button. Not to worry, personally still looking at the end of Q2 to make some money and I’ll take anything before then as a bonus. SP is frustrating but not of undue concern (at the moment anyway), be interesting to read Sir Marc’s Chairman’s statement this year, might finally put some meat on the bones!

Can you post any message or tweet to us all that confirms they dumped all their shares?

Good posts today although it helps I’ve filtered Hemotruth. Micky/Mr India, I’m sure most if not all people that heavily promoted HEMO did so with the best intentions. My take is that HEMO themselves thought Eli would take up the CDX option but for whatever reason they changed their minds at the last moment. I’m sure even Mint thought the same so embarked on a selling spree in order to get their money back. It’s a gamble that didn’t come off, **** happens I’m afraid which is why we’re not all millionaires sitting on a beach. It’s history now and we can all look forward to an excellent year. I’m convinced this SP will be in distant memory in a matter of weeks. A CBR announcement must be very soon, the FDA meeting is weeks away at most. I believe that CAR-T will be designated a breakthrough therapy and as such could proceed immediately to clinical trials. It’s only for 20 patients so clinical proof of concept could be achieved by Q2 if all goes well. Peer level companies at that stage are around £170m! CDX and Hu-PHEC in the pipeline as well. It’s only my opinion but I’d advise you keep the faith, have a little more patience (although I get the frustration). I’m sure by the end of this quarter you’ll (we’ll) all be feeling a lot better about things.

JHFH Don’t be an idiot and get lured in responding to that prat. Filter and ignore! He’s a trouble maker, always has been all be it under another name.

JHFH In a way Vlad did admit to the CLNs being a mistake. I tweeted early last year that it was extremely naive of management to take a verbal agreement from Mint that they wouldn’t convert and sell and I hoped lessons had been learnt..and he liked it. That being said it’s history and we move on, the important thing now is they are fully funded until at least the end of Q2.
My take on today’s RNS is one of pleasant surprise. I felt sure CDX would take a back seat and all focus would be on CAR-T and CBR, so I’m delighted CDX is running in parallel towards clinical trials. I’m of the opinion that SAFE HEMO CAR-T will get breakthrough therapy status from the FDA and as such will get fast tracked to clinical trials. I’m also of the opinion that CBR must be getting very close to having their initial results validated with pre-clinical studies being completed. For all we know they may have already concluded. So with my expectation of a fast tracked IND application for CAR-T, an update on CBR soon and today’s announcement of CDX and that IND application not far behind, there are only positives in my mind. If I’m right this SP will be a dim and distant memory in the coming weeks. I for one look forward to the coming weeks and months with tremendous optimism.

I did indeed get a reference code but there was no follow up email for me to access the conference.

Judging by the SP today I’m guessing that there was nothing in the presentation that we didn’t already know. No real surprise that Hemogenyx haven’t put in on their website like other attendees have, I’m not sure they’ll ever understand the meaning of PR.
That aside, the FDA meeting is fast approaching which means news won’t be long. In my opinion an IND application for CAR-T and a CBR update will both be out this quarter and from the whispers I hear CBR could be something quite special. Happy to wait.

Mr India. Hang in there my friend. I have a feeling this quarter is going to be pretty special. Definitely ‘when’ and not ‘if’ with Hemogenyx. Obviously just my opinion.

News coming this quarter for CAR-T and CBR. I’ve just bought another £12.5k worth at under 2p. Very very happy!

For information there are four types of leukaemia. The one eluded to in this trial was ALL which starts in the early form of white blood cells called lymphocytes in the bone marrow. Most cases of ALL occur in children, although most deaths occur in adults. Hemogenyx are focused on something very different, AML. This type of leukaemia is caused by abnormality in an early stage of myeloid cells in the bone marrow . Generally it’s a disease that affects older people (average age 68). Because it’s so aggressive treatment is considered much harder on the body. If memory serves I think there are around 20,000 cases in the USA alone every year. So in summary HEMO CAR-T is a very different treatment to the one mentioned.

JHFH It says my registration has been submitted successfully and I have the reference code to watch so here’s hoping.

Pawn Looks like I’m in. If so I’ll keep you all informed as to what he says.